



**Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)  
(Limited by Guarantee)**

**Trustees Report and Financial Statements**

Registered Charity Number: 1085527

Company Number: 04133242

<b>Contents</b>	<b>Page</b>
Trustees' Report	1 - 11
Auditors' report	12 - 13
Statement of Financial Activities	14
Balance sheet	15
Statement of cash-flows	16
Notes to the Accounts	17 – 27

**Trustees' Report**

**Legal and Administrative Information**

Year ended 31 December 2020

---

**Reference and administration details of the charity, its Trustees and advisors**

**Company Number: 04133242**

**Charity Number: 1085527**

***Patrons***

Mark Foster  
Giorgio Locatelli  
Jo Frost

***Hon. President***

David Reading OBE

***Trustees***

Trustees who are directors for the purpose of company law and trustees for the purpose of charity law, who served during the year, are as follows:

Mrs Sarah Lassman	Chair
Ms Alison Skinner	Hon. Treasurer – Retired April 2021
Mrs Sue Clarke	Retired December 2020
Mr Boaz Gaventa	
Dr Alison Walker-Fraser	
Dr Joanne Walsh	
Mr Chris Meads	Appointed December 2020
Mrs Louise Wilkinson	Appointed December 2020
Mrs Taj Randhawa	Appointed December 2020
Mr Peter Littleton	Appointed December 2020

***Chief Executive of Anaphylaxis Campaign***

Mrs J. L. Regent

***Registered office***

1 Alexandra Road  
Farnborough  
Hampshire GU14 6BU

***Operational Office***

1 Alexandra Road  
Farnborough  
Hampshire GU14 6BU

***Website:*** [www.anaphylaxis.org.uk](http://www.anaphylaxis.org.uk)

***Bankers***

***HSBC Bank plc***

54 High Street  
Epsom  
Surrey KT19 8DS

***Investment Advisors***

Hargreaves Lansdown  
One College Square South  
Anchor Road  
Bristol BS1 5HL

***Solicitors***

Stone King LLP  
Boundary Street  
91 Charterhouse Street  
London EC1M 6HR

***Independent Auditor***

Chamberlains  
Elm House  
Shackleford Road  
Elstead GU8 6LB

---

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the financial statements for the Year ended 31 December 2020.

## 2020 – Our Impact

- We continued to engage with allergy clinics across the UK during 2020 to support them as they managed their clinics remotely during the Covid 19 pandemic. We provided links to our Covid 19 Hub with 'Frequently asked Questions' to help them support their patients.
- We continued to promote the legislation which enables schools in England and Wales, from September 2017, to hold a spare adrenaline auto-injector in case of emergency. In addition, we continued to support the [www.sparepensinschools.uk](http://www.sparepensinschools.uk) website. This message was reinforced in 2020 through two mailings to 27,000 schools with an average open rate of 12%.
- Our Corporate Panel and our Clinical and Scientific Panel were both active throughout the year providing relevant advice to support our work.
- We took forward a programme of diversity training for all staff, trustees and for volunteers and collaborated with initiatives taken forward by clinical partners to address ethnic differences.
- We developed a toolkit of resources for GPs, pharmacists and practice nurses working in Primary Care to help them support their patients. We reached over 2,900 healthcare professionals.
- We continue to engage with legislators, regulators Local Authorities and individual food companies to improve food safety for the allergic population.
- We staged 7 webinars, with opportunities for questions, attended by 2,670 people including a webinar by Professor George Du Toit 'Managing your allergies in the time of Coronavirus'.
- We promoted the Anaphylaxis Campaign to all UK universities through a mailing. This had an opening rate of 17%. It included a new tops tips poster for starting university and promoted our Covid 19 hub. We shared our Youth Ambassador's podcast with tips for being an allergic student at university.
- We attended the Allergy Food Show in Glasgow where we gave advice to over 100 families.
- We responded to over 2,000 helpline enquiries by email, telephone and social media.
- Our work was featured in national and local press, including the BBC News, The Mirror, Sunday Post and New Food Magazine.
- 46,500 people undertook our AllergyWise courses in 2020 and this included over 42,000 completing the 'AllergyWise for Schools' course.
- Our fundraisers remained enthusiastic, committed and flexible during a challenging year. Many postponed planned events to a later date. Others completed challenges virtually, ensuring their fundraising efforts went ahead during 2020.
- Plans for Anaphylaxis Awareness Week changed from a fundraising initiative to *awareness raising* due to the distractions and complications of the pandemic. Despite the challenges faced by many fundraisers, over 100 people were involved in Anaphylaxis Awareness Week and an additional 75 participated in a virtual bake-off challenge. Over £7,000 was raised against a revised projected income target of £3,000.
- A significant, and unexpected, legacy of £102,965 was received in 2020 from the estate of Miss Penelope Sibson. The Will gave power of disbursement to two executors; one was Miss Sibson's goddaughter, whose son has a severe allergy to peanut, and wished for the Anaphylaxis Campaign to benefit from the estate in recognition of our advice.

---

## Company Information

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group) (the 'Campaign') was incorporated under the Companies Act on 29 December 2000 and is a company limited by guarantee. The Campaign was registered as a charity on 13 March 2001 and its governing document is a Memorandum of Association dated 29 December 2000. The Campaign is also recognised by HM Revenue & Customs as a charity for tax purposes.

### ***The objectives of the Campaign are:***

- 1. To advance the education and general understanding of the public concerning life-threatening allergies and associated disorders*
- 2. To protect the health of people who are at risk of severe allergic reactions by providing help and information to them, their families and friends.*
- 3. To promote research into the cause and care of severe allergic conditions and to publish the results of such research.*

### ***How the Campaign's objectives benefit the public.***

Severe allergic conditions, whether in a young child, teenager or adult, can have a devastating effect on everyday life, not just for those at risk, but also for their families. Our aim is to:

- raise allergy awareness for the benefit of all.
- help to protect the public by campaigning for improvements in food labelling.
- provide information of the highest quality via our helpline for allergy advice and information, our website and allergy courses, all of which are available to the general public.
- create a safer early years and school environment for all severely allergic children.
- increase the depth of knowledge that the food industry has with regard to allergy management.
- assist clinicians and other healthcare providers to have a greater understanding of severe allergy and anaphylaxis through our training programmes.
- support research into severe allergy and make the results available to the general public.

The Trustees have referred to the guidance contained in the Charity Commission's guidance on public benefit when reviewing our 3-year Strategic Plan, which set out our activities for the period 2019 – 2021 to meet our objectives.

### ***Objective 1. To advance the education and general understanding of the public concerning life-threatening allergies and associated disorders.***

#### ***What we said we would do: be the principal trusted source of information about anaphylaxis in the UK***

*a: through building and maintaining our reputation as a provider of quality information*

*b: through our training programmes*

*c: through our web site and social media*

*d: for the food industry*

*e: for clinicians*

---

***What we did in 2020:***

***a. through building and maintaining our reputation as a provider of quality information.***

- Our materials continue to be produced to a strict standard, being based on high quality evidence and reviewed by clinical experts and by volunteers of the Campaign.
- We revised and republished 3 knowledgebase articles and 5 factsheets with input from our Clinical and Scientific panel.
- We developed and published the Infant Weaning Guidance and promoted this at an Infant Weaning Conference in October 2020.
- We developed a Covid 19 hub which featured the latest information on Covid 19 vaccines and allergies from the Medicines and Healthcare Products Regulatory Agency (MHRA) and The Green Book. We partnered with Allergy UK and the British Society for Allergy and Clinical Immunology (BSACI) to develop 'Frequently Asked Questions'.
- The following webinars were held during 2020 and viewed by 2,670 people:
  - Isabel Skypala 'When Allergy & Nutrition Collide': 'Rise of Reactions to Plant Foods'
  - Professor George Du Toit 'Managing your allergies in the time of Coronavirus'
  - Moira Howie, Nutrition Advisor – 'Managing your allergies in the New Reality'
  - Peter Littleton, Christeys Food Hygiene Ltd – 'The Role of Cleaning in the Management of Allergens'
  - Helen Arrowsmith, Food Law Adviser, 'Allergen information for prepacked direct sale food'
  - Richard Fielder, Bio Check 'Food Allergen Testing, has it got more complicated?'
  - Tracey Dunn, our Education Ambassador and a Headteacher – 'Making schools safer'
- Media coverage took place where the Campaign was featured or quoted on allergy issues in the following:
  - inews: Nut free Restaurant Chain- provided stats/information for a news piece.
  - BBC News: featured on BBC News online, a story on the Emerade AAI recall.
  - New Food Magazine - third podcast: featured discussing the pandemic and how it affected people with allergies and dietary requirements.
  - The Mirror: 'toxic takeaways' we appeared in a story about how an increase in takeaway culture is having an impact on allergic reactions.
  - Sunday Post: covered our Anaphylaxis Awareness Week.
- Our volunteer-led Support Group network of 23 regular groups and many more operating on a more adhoc basis continue to be supported by our Outreach Coordinator. Group Meetings are actively supported by local clinicians who specialise in allergies. Through the pandemic in 2020, Support Groups have been held virtually via Zoom. Our "Allergy Buddy" volunteers support people on a one-to-one basis, by telephone or email. This scheme has become increasingly popular with people who want to offer support, but do not have time to coordinate groups. We currently have 14 allergy buddies across the country.

***b. through our training programmes***

- Our AllergyWise suite of online training courses cover the vital basic information about signs and symptoms of severe allergy and anaphylaxis, emergency treatment, allergen avoidance and longer-term management of severe allergy.
- 46,500 people completed our AllergyWise courses in 2020 up 185% from 2019.
- AllergyWise for Healthcare Professionals, our "Train the Trainers" course, was re-accredited by the Royal College of Nursing and continues to be taken up by school and community nurses, first aid trainers and others who have responsibility for caring for people with severe allergies.

---

***c. engagement achieved through our website, courses and social media platforms***

- Visitors to our website grew by over 6% to 684,800 people in 2020. The number of those looking to take our AllergyWise e learning courses grew by 122% to over 70,000 people.
- Our social media following increased by 5.7% on Facebook, 43% on Twitter, 41% on LinkedIn and 35% on Instagram and our YouTube videos were viewed over 28,000 times.
- Our most viewed page on the website was the Covid Vaccine hub with over 1 million page views. Our most viewed patient information resource was the Legumes and Pulses knowledgebase resource with over 50,000 page views.

***d. for the food industry***

- The Corporate Panel met three times in 2020 providing guidance and expertise across the retail and service sectors where it impacted on allergic consumers.
- Bi-monthly e-newsletters for our corporate members maintained a steady flow of updates on relevant research on food allergens, testing methods, and regulatory changes. On average our corporate newsletter was dispatched to over 400 contacts and had an open rate of 20%.
- We responded through our Helpline to hot topics from industry, particularly the food sector, due to the planned changes to the regulations on labelling regarding pre-packed for direct sale foods coming into effect in October 2021. We also answered queries from food companies concerning technical issues on ingredients. Caterers expressed particular concerns about providing accurate information for food allergic customers.
- Our Covid 19 hub has information for food business who were affected in a variety of different ways and have had to adapt their business models to frequently changing rules and regulations. We provide information to help them comply with relevant allergen and hygiene regulations.
- We participated in the consultation process for the update to the 'Food Allergen Labelling and Information: Technical Guidance' for the upcoming changes for pre-packed for direct sale foods (Natasha's law) coming into effect in October 2021. The updated guidance was published in 2020.
- Our CEO spoke at a number of conferences and training events including Dunbia Food Safety Week, The Society of Food Hygiene and Technology conference and ADM Protexin Training Day, as well as several online events.

***e. for clinicians***

- We provided accredited training through our online AllergyWise programme to over 300 GPs, practice nurses, school nurses and other healthcare professionals. We continued to signpost our AllergyWise courses, and our patient and healthcare information to allergy clinics.
- We sent bi-monthly newsletters to our healthcare members which signposted to our patient materials and AllergyWise training courses. They also featured many articles including information on immunotherapy, the latest news on Covid 19 vaccination and allergies, NICE guidance, the latest allergy hospital admissions data from the NHS and updates on the current situation with regards to adrenaline auto-injectors. These bi-monthly newsletters had an average open rate of 41%.
- We developed a comprehensive webinar programme for healthcare professionals which included webinars by Isabel Skypala – talking about when 'Nutrition and Allergy Collide' and Dr Helen Howells on Prescribing Adrenaline Auto Injectors.

- 
- The Clinical and Scientific Panel was relaunched with Professor John Warner as its new chair in the summer of 2020, bringing together allergy expertise from across the country to inform the work of the Anaphylaxis Campaign.
  - We actively engaged in work with clinical partners to develop research to look at how ethnicity issues impact on those affected by severe allergies.

***Objective 2. To protect the health of people at risk of severe allergic reactions by providing help and information to them, their families and friends.***

***What we said we would do: Campaign on behalf of people at risk of severe allergic reactions***

***What we did in 2020:***

- **We worked with other key agencies to effect improvements in services for severely allergic people nationally and internationally.** During the year, the Campaign continued to be involved at the highest level with government, medical and voluntary organisations, such as the Food Standards Agency, British Society for Allergy and Immunology and European Academy of Allergy and Immunology.
- We continue to work closely with bereaved families and to consider the information in Coroners reports.

**As part of our Universities and Adults project:**

- We worked in partnership in the University Catering organisation (TUCO) to support young people with allergies through the Covid 19 pandemic with the publication of an article on the TUCO website. With our Youth Ambassador we developed a Q&A podcast to reach out to young people at home and university which has been viewed 222 times.

**As part of our Making Schools Safer Project:**

- Tracey Dunn gave a webinar entitled 'Making Schools Safer - Allergies and Covid 19' which was oversubscribed and then repeated 10 days later. We collaborated with one of our volunteers to update our key stage 1 and 2 resources for schools.
- Our CEO made a film with ITN for the BSACI conference in October 2020 talking about AllergyWise, spare pens in schools and carrying two adrenaline auto Injectors.

**As part of our Food Services Project:**

We used our database of Local Authorities and Trading Standards to share best practice and learnings from coroner inquests in two mailings opened by 136 local authorities.

- We worked in partnership with the Food Standards Agency to consult on the updated technical guidance issued in advance of the introduction of 'Natasha's Law' in October 2021.
- We worked with Codex Alimentarius, the organisation that develops international food trade standards, to represent the voice of the allergic consumer on their work to revise the allergen provisions of the General Standard for labelling of pre-packaged foods.
- Following the COVID-19 outbreak, we provided detailed information and links for food businesses, who had to rapidly adapt, on our website COVID-19 pages.



**As part of our Primary Care Project:**

- We developed a toolkit for Primary Care providing clinically based information on diagnosis, treatments, prescribing and resources. We have mailed these to Clinical Commissioning Groups, Local Medical Committees and healthcare professional members to support the provision of outstanding care to allergy patients. Working with the Pharmacy Defence Association we reached over 2,900 healthcare professionals with these resources.
- We produced a toolkit for pharmacists to help support patients who have a severe allergic reaction to their vaccinations and also ensure patients carrying adrenaline auto-injectors (AAIs) for severe allergies are trained in how to use them correctly. This was sent to over 30,000 pharmacists.

***Objective 3. To promote research into the cause and care of severe allergic conditions and to publish the results of such research.***

***What we said we would do: support and fund research that improves services and quality of life for patients: What we did in 2020:***

***Facilitated many research projects*** – the Campaign assisted the following organisations with research projects into severe allergies during 2020:

- Worked in partnership with DBV on their Qualitative Evaluation of Health-related Quality of Life Associated with Peanut Allergy: Patient and Carer Vignette and Burden of Illness Study.
- Working in partnership with Aimmune to support the dissemination of the Peanut Allergy/Quality of Life survey.
- Working in partnership with Aimmune to recruit families for a study regarding allergy Disease Awareness/Media Work.
- Working with the Food Standards agency to recruit families for a cost of living with allergy study.

**Structure, Governance and Management**

The Campaign's Memorandum of Association sets out the objects and powers of the charitable company and is governed under its Articles of Association. Under those Articles, the Trustees are elected at the Annual General Meeting to serve for a period of approximately three years.

Trustees are recruited to ensure a balanced board with a mix of skills. All new Trustees are given an induction which includes learning about the background, ethos and day to day activities of the Campaign as well as outlining their responsibilities. The maximum number of Trustees allowed by the Campaign's governing document is eleven and at 31 December 2020 there were nine. Trustees may be co-opted by the board as considered necessary and those co-opted may serve until the Annual General Meeting following their co-option, at which time they must stand for election if they wish to remain on the Board.

The Governance structure is made up of a Board of Trustees. The Chief Executive is not a Trustee but a permanent non-voting member of the Board, with the right to attend all Board meetings unless a conflict of interest exists. The Business Manager for the Campaign is also its Company Secretary. Other members of staff from the Campaign attend as required.

---

The Board usually meets quarterly and holds an annual Strategy Day in addition, which all Trustees and the Chief Executive are expected to attend. Trustees may also attend any of the Campaign's conferences and events relevant to their particular roles during the year. From the beginning of April 2020 to December 2020 Board meetings were held monthly via Zoom.

The Campaign operates in a consistent way by following the policies set out and agreed by the Board, supported and implemented by the Chief Executive, Mrs. Lynne Regent and her staff. Day to day responsibility rests with the Chief Executive, who is responsible for all staff.

### **Strategy 2019-2021**

The key objectives for 2019-2021 were set out in the Business Plan 2019 agreed by the Board in March 2019. The key priorities for the Campaign were agreed as follows;

- Improve safety and quality of life for people affected by anaphylaxis
- Grow the reach of the Campaign increasing profile and awareness of our work
- Help achieve wider NHS availability of oral immunotherapy to key allergens in partnership with pharmaceuticals (ALK, Aimmune, DBV).
- Engage with Government on critical allergy related initiatives. Develop strong relationships with key Ministers, Parliamentary groups, focussing on Health, Education and Industry
- Generic AAls to be available in most schools and address key issues in adrenaline provision
- Increase uptake of AllergyWise training programmes in schools
- Working with universities to develop education resources appropriate for this target group (especially Freshers)
- Help food industry and services become safer through better labelling and information with improved application of regulatory standards and controls.
- Help achieve fewer anaphylaxis fatalities and support those bereaved by anaphylaxis in an effective way.
- Aim to get to an active support group meeting in each county.

The Business plan has been monitored by the Board at each of their meetings. The performance objectives of each member of staff directly relate to the Business Plan and the overall strategic direction.

From April 2020 all staff worked virtually from home with full electronic, but secure access to central files. With technical support the Helpline and Information Team provided a full service as demand for our advice increased markedly in 2021. Our CEO held weekly virtual meetings with all staff participating via a sound and visual link as well as one to one meetings. A member of staff visited our office on a weekly basis to process incoming post. During this period all staff received diversity training.

### **Investment performance achieved against investment objectives**

The investment objectives of the Campaign are to maximise the value of reserves, while avoiding undue risk. The Campaign's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Campaign's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a loss of £6,941 on the value report at the end of December 2019 (£163,091). The value at the end of December 2020 was £156,150.

**Financial review   Reserves policy**

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Campaign, the Trustees have established a policy whereby the unrestricted reserves held by the Campaign should equate to at least six months operating cost. At the year end this equated to £252,384. Free reserves (excluding 6 months operating costs) at 31 December 2020 stood at £300,954.

**Restricted reserves**

Details of restricted funds are shown in note 16 of the financial statements.

**Risk review**

The Trustees have conducted a review of the major risks to which the Campaign is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Campaign going forward. Key risks for the Campaign include potential for loss of expertise and/or revenue from donations and fundraising activities. All Trustees received regular governance training.

**Financial overview**

The Campaign ended the year in a sound financial position with £7,496 already in hand to fund projects in 2021 and sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £495,062. Unrestricted funds were £553,338 and restricted funds £7,496. COVID has had a significant impact on the operations of the Anaphylaxis Campaign, including the need to change employment contracts to deal with furlough. Detailed consideration is being given to further changes to the organisation that might be implemented. As a consequence, legal fees have been considerably higher in the year under review.

**Financial policies**

All payments up to £10,000 made by the Campaign have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Campaign is delegated to the Business Manager who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered at each meeting of Trustees.

**Principal funding sources**

The principal funding sources for the Campaign are donations from a variety of individuals and Gift Aid and membership subscriptions. The Campaign seeks funds from companies, charitable trusts and other sources to fund running costs and specific projects.

We are particularly grateful for grants from the Barbara Ward Children's Foundation and the Garfield Weston Foundation.

**Uses of funds**

The funds received by the Campaign during the year have helped to finance our Helpline and Information services, Support Group development, Adult Allergy campaigns, outreach to young people with severe allergies, research programmes, and our training for health professionals.

### **Plans for the future**

The Board have agreed a Strategic Framework for 2019-2021. The general impact the Anaphylaxis Campaign aims to achieve by the end of 2021 is:

- Improved safety and quality of life for people affected by anaphylaxis including clinical, practical and psychological aspects.
- Wider reach to more people affected by anaphylaxis and ensuring that more organisations interacting with people with anaphylaxis know about the Anaphylaxis Campaign and are supported by our information and services.
- Campaigning for society -wide positive change for those with anaphylaxis, by influencing at government level on critical issues.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan approved by the Board in March 2019. These priorities are reflected in the Business Plan which were approved by the Board in March 2019. The main areas for future work will be:

- **Early Years and Schools;** Help to keep children safe by providing information, training and support in early years and schools settings
- **Universities and Adults:** Help adults of all ages stay safe, with a special focus on young adults (16-24) with anaphylaxis, helping them to manage the transition of moving away to college /university/own home and employment
- **Food:** Help the food industry become safer through better labelling, and information provision, and improved application of regulatory standards, and controls.
- **Primary Care:** working with Clinical Commissioning Groups to improve the quality of prescribing and dispensing of Adrenaline Auto Injectors across Primary Care
- **Fatalities:** Share learning from anaphylaxis fatalities and support those bereaved by anaphylaxis in an effective way.

The Board will agree a new strategic direction in 2021 for 2021 to 2023. Also a consultation was held in December 2020 regarding proposed constitutional changes for the charity. It is envisaged that these changes will be implemented in 2021.

---

**Statement of Trustees' responsibilities**

The trustees (who are also directors of the Campaign for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Auditor**

Chamberlains were appointed auditors at the Annual General Meeting of the Campaign held on 11<sup>th</sup> December 2019. The AGM for 2020 was deferred.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

This report was approved by the Trustees on 28 June 2021 and signed on their behalf.

Mrs. Sarah Lassman  
**Chair**

# **Independent Auditor's Report to the Members of The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group)**

## **Opinion**

We have audited the financial statements of The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group) (the 'charitable company') for the year ended 31 December 2020 which comprise statement of financial activities, balance sheet and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

## **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

## **Other information**

The trustees are responsible for the other information. The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard

## **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

## **Matters on which we are required to report by exception**

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

## **Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 11 the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

## **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.

## **Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Paul Chamberlain (Senior Statutory Auditor)  
For and on behalf of Chamberlains Statutory Auditors and Chartered Accountants  
Elm House, Tanshire Park  
Shackleford Road, Elstead  
Godalming, Surrey  
GU8 6LB

Date: 26 July 2021

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Statement of financial activities (incorporating an income and expenditure account)

Year ended 31 December 2020

	Notes	Unrestricted funds £	Restricted Funds £	Total 2020 £	Unrestricted funds £	Restricted funds £	Total 2019 £
<b>Income from:</b>							
Donations	2	382,487	63,387	<b>445,874</b>	340,212	36,000	376,212
Other trading activities	2	77,668	-	<b>77,668</b>	96,664	-	96,664
Income from investments	3	1,582	-	<b>1,582</b>	1,998	-	1,998
Income from charitable activities	2	97,157	-	<b>97,157</b>	81,734	-	81,734
<b>Total income</b>		<b>558,894</b>	<b>63,387</b>	<b>622,281</b>	<b>520,608</b>	<b>36,000</b>	<b>556,608</b>
<b>Expenditure on:</b>							
Raising funds		28,188	-	<b>28,188</b>	27,408	-	27,408
Charitable activities		384,097	82,776	<b>466,874</b>	488,587	20,354	508,941
<b>Total expenditure</b>	4	<b>412,285</b>	<b>82,776</b>	<b>495,062</b>	<b>515,995</b>	<b>20,354</b>	<b>536,349</b>
Net (losses)/gains on investments	11	(6,941)	-	<b>(6,941)</b>	15,866	-	15,866
<b>Net income/(expenditure)</b>		<b>139,668</b>	<b>(19,389)</b>	<b>120,279</b>	<b>20,479</b>	<b>15,646</b>	<b>36,125</b>
<b>Transfer between funds</b>		28,756	(28,756)	-	4,533	(4,533)	-
Net movement in Funds		168,424	(48,145)	120,279	25,012	11,113	36,125
<b>Reconciliation of funds:</b>							
Total funds brought forward		384,914	55,641	<b>440,555</b>	359,902	44,528	404,430
<b>Total funds carried forward</b>	15 / 16	<b>553,338</b>	<b>7,496</b>	<b>560,834</b>	<b>384,914</b>	<b>55,641</b>	<b>440,555</b>

The Statement of financial activities includes all gains and losses in the year.

All income and expenditure derive from continuing activities.



## Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

### Balance Sheet

Year ended 31 December 2020

	Note	2020 £	2019 £
<b>Fixed Assets</b>			
Tangible assets	10	15,407	23,762
Investments	11	156,150	163,091
		<u>171,557</u>	<u>186,853</u>
<b>Current assets</b>			
Stock		2,193	2,548
Debtors	12	64,051	73,642
Cash at bank		357,362	222,985
		<u>423,606</u>	<u>299,175</u>
<b>Creditors - amounts falling due within one year</b>	13	(34,329)	(45,473)
Net current assets		389,277	253,702
<b>Total assets less current liabilities</b>		<u><b>560,834</b></u>	<u><b>440,555</b></u>
<b>Funds</b>			
Restricted funds	16	7,496	55,641
Unrestricted funds	15	553,337	384,914
<b>Total funds</b>		<u><b>560,833</b></u>	<u><b>440,555</b></u>

These financial statements have been prepared in accordance with the special provisions of Section 15 of the Companies Act 2006 relating to small companies.

Approved by the Trustees and authorised for issue on 16 May 2021 and signed on their behalf by:

Sarah Lassman - Trustee

**Company Registration Number: 04133242**

The notes on pages 17 to 28 form part of these financial statements.

## Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

### Statement of Cash Flows

Year ended 31 December 2020

	Note	2020 £	2019 £
<b>Cash flows from operating activities</b>	<b>20</b>	<b>134,292</b>	<b>16,463</b>
<b>Cash flows from investing activities</b>			
Purchase of fixed assets		(1,497)	(12,343)
Interest received		1,582	1,998
<b>Net cash flow from investing activities</b>		<b>85</b>	<b>(10,345)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>134,377</b>	<b>6,118</b>
<b>Cash and cash equivalents at beginning of year</b>		<b>222,985</b>	<b>216,867</b>
<b>Cash and cash equivalents at end of year</b>		<b>357,362</b>	<b>222,985</b>

**Notes to the financial statements**

Year ended 31 December 2020

---

**1. Accounting policies**

**General information**

The Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group) is a company limited by guarantee in the United Kingdom. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information on page 2 of these financial statements. The nature of the charity's operations and principal activities are to: a) advance the education and general understanding of the public concerning life-threatening allergies and associated disorders; b) to protect the health of people who may be at risk of severe allergic reactions by providing help and information to them, their family and friends; and c) to promote research into the cause and care of severe allergic conditions and to publish the results of such research.

The charity constitutes a public benefit entity as defined by FRS102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) issued on 16 July 2014, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006 and UK Generally Accepted Practice.

**Basis of preparation**

The financial statements have been prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value.

The financial statements are prepared in sterling and monetary amounts are rounded to the nearest £.

The significant accounting policies applied in the preparation of these financial statements are set out below.

These policies have been consistently applied to all years presented unless otherwise stated.

**Tangible Fixed Assets**

All fixed assets to a value of £50 or more are capitalised at cost. Depreciation is provided on all fixed assets at rates calculated to write off the cost of the asset over its expected useful life as follows:

Equipment: 25% straight line on cost

**Income recognition**

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

**Donations and subscriptions**

Membership donations, memorial donations, major donors, legacies and charitable trust income is recognised on a receipts basis.

Corporate donations, corporate membership and professional membership income is recognised on a receivable basis.

## Notes to the financial statements (continued)

Year ended 31 December 2020

---

### 1. Accounting policies (continued)

#### Income recognition (continued)

##### Donations and subscriptions (continued)

Individual membership received by direct debit is recognised on a receivable basis. For those members who pay by cheque or credit card, recognition is on a received basis.

Gift Aid income includes the Gift Aid on all applicable donations received in the year under review.

#### Gifts in kind

Donated professional services are recognised in income at their fair value when their economic benefit is probable, it can be measured reliably and the Campaign has control over the item. Fair value is determined on the basis of the value of the gift to the charity. For example the amount the charity would be willing to pay in the open market for such services. A corresponding amount is recognised in expenditure.

#### Community fundraising

Income is recognised on a received basis.

#### Event income and corporate sponsorship

Income earned from fundraising and sponsored events is recognised on the date the event is held.

#### Sale of educational products

Income is received for the sale of online "AllergyWise" courses written by the Campaign. Income is recognised on a received basis.

#### Product recall income

Product recall income is income received from retailers for the Campaign, contacting their members about mislabelled products. The invoiced amount is based on the type of product mislabelled, the difference types of alerts sent and the membership status of the retailer. Income is recognised on a receivable basis net of VAT.

#### Investment income

Investment income is earned through holding assets for investment purposes, and includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Investment income is recognised on a received basis.

## Notes to the financial statements (continued)

Year ended 31 December 2020

---

### 1. Accounting policies (continued)

#### Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate

Costs of raising funds:	includes all direct fundraising costs, including costs of staff specifically engaged in community, trust and corporate fundraising.
-------------------------	-------------------------------------------------------------------------------------------------------------------------------------

Costs of charitable activities:	includes all costs (including support costs) for the Campaign's activities in meeting our charitable objectives.
---------------------------------	------------------------------------------------------------------------------------------------------------------

Governance costs:	includes costs incurred in the governance of the charity and its assets, primarily associated with constitutional and statutory requirements.
-------------------	-----------------------------------------------------------------------------------------------------------------------------------------------

#### Support costs allocation

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office expenses, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributable to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. Premises and other overheads have been allocated on an accruals basis.

Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The analysis of these costs is included in note 5.

#### Debtors

Trade and other debtors are recognised at the settlement amount due after any discounts offered to members. Prepayments are valued at the amount prepaid.

#### Cash at bank

Cash at bank includes cash and fixed term deposit accounts with a short term maturity of twelve months.

#### Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any discounts due.

#### Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the Campaign. Designated funds are unrestricted funds of the charity which the Trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Campaign's work or for specific projects being undertaken by the Campaign.

## Notes to the financial statements (continued)

Year ended 31 December 2020

---

### 1. Accounting policies (continued)

#### Leasing

Rentals payable under operating leases are charged against income on a straight line basis over the lease term.

#### Taxation

The charitable company's activities are exempt from taxation under Sections 466-493 of the Corporation Tax Act 2010.

#### Investments

The carrying value of the investment at the accounting date represents the fair value of the underlying quoted investments and deposits.

The net realised and unrealised gains and losses of the underlying investments are reflected through the statement of financial activities.

#### Pensions

The charity operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

# Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

## Notes to the financial statements (continued)

Year ended 31 December 2020

### 2. Incoming resources

<b>Donations</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Membership donations	30,595	31,669
Memoriam donations	7,340	34,645
Corporate donations	4,414	15,407
Charitable trust income & major donors	56,550	39,300
Legacies	103,965	2,000
Gift aid	18,814	21,290
Community fundraising	42,734	84,831
Individual membership	55,701	59,521
Professional membership	6,252	6,281
Corporate memberships	64,115	68,260
Other - including COVID support funding	55,393	13,008
	<b>445,873</b>	<b>376,212</b>

Included in legacies are amounts of £102,965 from the estate of Penelope Sibson and £1,000 from the estate of Wendy Thomson.

<b>Other trading activities</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Sale of goods	4,668	5,681
Advertising	720	970
Event income	-	25,791
Corporate sponsorship	-	16,250
Special project income	63,687	37,369
Other	8,593	10,603
	<b>77,668</b>	<b>96,664</b>

<b>Charitable activities</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Sale of education products	36,932	25,223
Product recall income	60,225	56,511
	<b>97,157</b>	<b>81,734</b>

<b>3. Income from investments</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Bank Interest	<b>1,582</b>	<b>1,998</b>

# Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

## Notes to the financial statements (continued)

Year ended 31 December 2020

<b>4. Total expenditure</b>	<b>Activities undertaken directly £</b>	<b>Support costs £</b>	<b>Total 2020 £</b>	<b>Total 2019 £</b>
Raising funds	28,188	-	28,188	27,408
Charitable activities	219,243	221,317	440,560	485,821
Governance costs	-	26,314	26,314	23,121
<b>Total</b>	<b>247,431</b>	<b>247,631</b>	<b>495,062</b>	<b>536,350</b>

## 5. Allocation of support costs

	<b>Basis of apportionment</b>	<b>Support costs £</b>	<b>Total 2020 £</b>	<b>Total 2019 £</b>
Staff costs	Staff time	92,246	92,246	82,930
Office rental and other office costs	Invoiced events	70,853	70,853	74,467
Travel expenses	Non-governance expenses	1,554	1,554	9,644
Legal / Professional costs	Invoiced events	26,706	26,706	3,790
Finance expenses	Bank charges payable	5,195	5,195	4,727
Website costs	Software cost and usage	5,617	5,617	7,072
Depreciation	Estimated useful life	9,852	9,852	13,327
Other costs	Invoiced events	9,294	9,294	13,245
		<b>221,317</b>	<b>221,317</b>	<b>209,202</b>

## 6. Allocation of governance costs

	<b>Activities undertaken directly £</b>	<b>Total 2020 £</b>	<b>Total 2019 £</b>
Staff costs	19,086	19,086	15,143
Audit fees	5,750	5,750	6,500
Travel and subsistence expenses	1,478	1,478	1,478
	<b>26,314</b>	<b>26,314</b>	<b>23,121</b>



## Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

### Notes to the financial statements (continued)

Year ended 31 December 2020

#### 7. Staff

The average monthly number of employees and full time equivalent (FTE) during the year was as follows:

	2020 Number	2020 FTE	2019 Number	2019 FTE
Raising funds	3	2	3	2
Charitable activities	10	8	10	8
Governance	-	-	-	-
	<u>13</u>	<u>10</u>	<u>13</u>	<u>10</u>

The total staff costs and employees benefits was as follows:

	2020 £	2019 £
Staff costs		
Wages & salaries	277,830	295,303
Employers NI	17,208	19,380
Pension costs	4,865	5,122
	<u>299,903</u>	<u>319,805</u>

None of the Trustees was employed by the Campaign, or had any interest in any contracts with the Campaign in either year. During the year £302 in respect of travel was reimbursed to two Trustees for expenditure incurred on the Campaign's business (2019: £1,189 - three Trustees).

No employee was paid more than £60,000 in either 2020 or 2019.

The key management personnel of The Campaign is the Chief Executive Officer, whose employee benefits total £53,796 (2019: £52,162).

#### 8. Net income / (expenditure) for the year

The net income / (expenditure) is stated after charging / (crediting):	2020 £	2019 £
Depreciation of tangible fixed assets	9,852	13,327
Operating lease rentals	<u>29,000</u>	<u>29,000</u>

#### 9. Auditor's remuneration

The auditor's remuneration amounts to an audit fee of £5,000 (2019: £5,000)

## Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

### Notes to the financial statements (continued)

Year ended 31 December 2020

---

#### 10. Fixed assets

<b>Cost</b>	<b>Equipment £</b>
At 1 January 2020	122,498
Additions	1,497
Disposals	(37,877)
At 31 December 2020	<u><b>86,118</b></u>
<b>Depreciation</b>	
At 1 January 2020	98,736
Charge for the year	9,852
Disposals	(37,877)
At 31 December 2020	<u><b>70,711</b></u>
<b>Net book value</b>	
At 31 December 2020	<u><b>15,407</b></u>
At 31 December 2019	<u><b>23,762</b></u>

# Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

## Notes to the financial statements (continued)

Year ended 31 December 2020

### 11. Investments

	2020 £	2019 £
Market value at 1 January	163,091	147,225
Additions	-	-
Disposals	-	-
Unrealised (loss)/gain on revaluation	(6,941)	15,866
<b>Market value at 31 December</b>	<b>156,150</b>	<b>163,091</b>

	2020		2019	
	Market value £	Cost £	Market value £	Cost £
Quoted investments				
UK - equities	155,115	132,963	161,479	132,963
Cash fund	1,035	1,035	1,612	1,612
	<b>156,150</b>	<b>133,998</b>	<b>163,091</b>	<b>134,575</b>

Included in the market value of investments at 31 December 2020 individual investments that are material to the investment portfolio valuation were:

	No. of ordinary shares / units	Market value	Cost at 31 December 2020	Percentage of total valuation
HL Multi-Manager Income & Growth Trust	73,493	£ 63,513	£ 56,392	40.7%
HL Multi-Manager Strategic Bond Trust	40,872	£ 63,629	£ 52,364	40.7%
HL Multi-High Income Trust	15,731	£ 15,960	£ 16,193	10.2%

The income shown above is after management fees.

### 12. Debtors

	2020 £	2019 £
Trade debtors	18,279	29,630
Prepayments	38,934	32,604
Accrued income	4,758	5,040
HMRC VAT liability (repayment)	2,080	6,368
	<b>64,051</b>	<b>73,642</b>

# Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

## Notes to the financial statements (continued)

Year ended 31 December 2020

<b>13. Creditors</b>	<b>2020</b>	2019
	£	£
Trade creditors	3,723	22,358
Other taxation and social security	5,283	6,908
Accruals	8,691	7,327
Deferred income (see note 14)	16,632	8,880
	<b>34,329</b>	<b>45,473</b>
<b>14. Deferred income</b>	<b>2020</b>	2019
	£	£
Income received in advance	<b>16,632</b>	<b>8,880</b>
	<b>2020</b>	2019
	£	£
At 1 January 2019	8,880	5,670
Amount released to incoming resources	(8,880)	(5,670)
Amount deferred in the year	16,632	8,880
<b>As at 31 December 2019</b>	<b>16,632</b>	<b>8,880</b>
Income in support of 2021 activities was the following:		
Corporate Subscriptions	8,880	8,880
	<b>8,880</b>	<b>8,880</b>

Income has been deferred for the above sponsorship, donations and subscriptions as they relate to events which are due to take place in 2021.

## 15. Unrestricted funds

	At 1 January 2020	Incoming resources	Outgoing resources	Gain on investment	Transfer to/from unrestricted	At 31 December 2020
	£	£	£	£	£	£
General fund	384,914	558,894	(412,285)	(6,941)	28,756	553,338
	<b>384,914</b>	<b>558,894</b>	<b>(412,285)</b>	<b>(6,941)</b>	<b>28,756</b>	<b>553,338</b>

## Name of unrestricted fund

General fund

## Description, nature and purpose of the fund

The 'free reserves' after allowing for all designated funds.

# Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

## Notes to the financial statements (continued)

Year ended 31 December 2020

### 16. Restricted funds

	At 1 January 2020 £	Incoming resources £	Outgoing resources £	Transfer to/from unrestricted £	At 31 December 2020 £
Isle of Man Fund	6,293				6,293
Support for Adults	8,199		(8,199)		-
Support for Pharmacies	12,393		(12,393)		-
Mylan Spare Pens	28,756			(28,756)	-
Support for Primary Care		10,000	(10,000)		-
Campaign for CCGs		4,500	(4,500)		-
Webinar for General Practice		1,500	(1,500)		-
DBV/Bresmed Project		232	(232)		-
Making Schools Safer Project		14,000	(14,000)		-
Back to School Campaign		22,500	(22,500)		-
Review of Educational Material		780	(780)		-
Switch Campaign		1,750	(1,750)		-
Mylan Speed Campaign		2,252	(2,252)		-
FSA Research Project		4,000	(3,700)		300
Survey, Review and Report		1,873	(970)		903
	<b>55,641</b>	<b>63,387</b>	<b>(82,776)</b>	<b>(28,756)</b>	<b>7,496</b>

### 17. Analysis of net assets between funds

	Unrestricted £	Restricted £	Total 2020 1	Total 2019 £
Fixed tangible assets	15,407	-	15,407	23,762
Fixed investment	156,150	-	156,150	163,091
Current assets	416,110	7,496	423,606	299,175
Current liabilities	(34,329)	-	(34,329)	(45,473)
	<b>553,338</b>	<b>7,496</b>	<b>560,834</b>	<b>440,555</b>

### 18. Operating leases

Future minimum payments under non-cancellable operating leases are £36,250 (2019: £65,250).

### 19. Pensions

The charity operates a defined contribution pension plan for its employees. The amount recognised as an expense in the year was £4,865 (2019: £5,122) included within unrestricted charitable activities and support costs.

### 20. Reconciliation of Net Movement in Funds to Net Cash Flow from Operating Activities

	2020 £	2019 £
Net movement in funds	<b>120,279</b>	36,125
Add back depreciation	<b>9,852</b>	13,327
(Deduct)/add back (gains)/losses on investments	<b>6,941</b>	(15,866)
(Deduct) interest income	<b>(1,582)</b>	(1,998)
(Increase)/decrease in stock	<b>355</b>	(677)
(Increase)/decrease in debtors	<b>9,591</b>	(28,856)
Increase/(decrease) in creditors	<b>(11,144)</b>	14,408
Net cash generated in operating activities	<b>134,292</b>	<b>16,463</b>

# Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

## Detailed income and expenditure account

Year ended 31 December 2020

	2020		2019	
	£	£	£	£
<b>Income</b>				
Subscriptions		126,068		134,062
Donations - members		30,595		31,669
Donations - other		246,477		125,650
Product Alerts income		60,225		56,511
Advertising & Sponsorship		720		17,220
Sale Proceeds		41,600		30,904
Community fundraising & events		42,734		110,622
Special project income		63,687		37,369
Other sundry income		8,593		10,603
Bank interest		1,582		1,998
		<u>622,281</u>		<u>556,608</u>
Cost of sales (net of closing stock value)		<u>(2,798)</u>		<u>(3,489)</u>
		619,483		553,119
<b>Expenditure</b>				
Wages & salaries	299,903		319,805	
Subcontract consultants	27,141		24,526	
Communications, magazine, design	5,198		7,961	
Website	5,617		7,072	
Fundraising expenses	6,335		10,279	
Conferences & events	1,650		20,955	
Office expenses	1,881		3,134	
Rent & rates	31,541		31,454	
Light & heat	1,342		4,173	
Staff training	(84)		2,991	
Staff recruitment	-		10,335	
Telephone & internet	4,355		4,550	
Stationery & printing	1,117		1,779	
Postage & carriage	3,973		5,329	
Photocopying	320		1,055	
Travel, subsistence & accommodation	3,032		11,122	
Computer and software	23,917		20,752	
Insurance	2,407		2,241	
Bank charges	5,195		4,727	
Audit	5,750		6,500	
Professional fees	26,706		3,790	
Depreciation	9,852		13,327	
Subscriptions & journals	770		748	
Sundry	487		1,162	
Irrecoverable VAT	8,037		11,335	
Bad debts	-		-	
Special Projects & research grants	15,731		1,122	
Support Groups	90		636	
		<u>(492,263)</u>		<u>(532,860)</u>
Surplus for the year from operations		127,220		20,259
Gain/loss on investments		<u>(6,941)</u>		<u>15,866</u>
Total surplus for the year		<u>120,279</u>		<u>36,125</u>